Please login to the form below

Not currently logged in
Email:
Password:

Spain passes cost-cutting generics law

Spain has passed a law to force doctors and pharmacists to prescribe generic brands as part of measures to reduce government spend

Spain has passed a law to enforce the prescribing and dispensing of generic drugs rather than the more expensive brands, in an attempt to save €2.4bn (£2.1bn) a year.

Doctors in Spain will now have to complete prescriptions giving only the details of the active ingredients of the medicine that their patients must take, as well as the dose and format. Pharmacies will be obliged to provide the cheapest available versions of drugs, which are paid for partly by the state and partly by patients.

The move is designed to help reduce Spain's budget deficit as the government works to bring it down to 6 per cent by the end of 2011.

Josu Erkoreka, Basque nationalist deputy, said: "It means an important saving for the public accounts and will, without doubt, benefit most people who use public health services.

"The interests of the big drugs companies must give way to public interest, and what matters is reducing the deficit and lowering the drugs bill for millions of people who use public health services."

However, it is feared that the move will lead to job losses in the pharma sector.

25th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FleishmanHillard

Latest intelligence

MORE MONEY FOR THE NHS – BUT IS THIS THE ANSWER?
Paul Mannu of Cello Health Insight says that politicians opening their pre-election cheque books can’t put the NHS where it needs to be – but pharma can play a major...
Medius Deal Watch
Pharma deals in February 2015
Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations...
Medius Deal Watch
Medius Deal Watch table for February 2015
The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals...

Infographics